Stay updated on Nivolumab and Ipilimumab in ACC Clinical Trial
Sign up to get notified when there's something new on the Nivolumab and Ipilimumab in ACC Clinical Trial page.

Latest updates to the Nivolumab and Ipilimumab in ACC Clinical Trial page
- Check6 days agoChange Detected- Footer revision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedAdded Revision: v3.4.2 and removed the funding-lapse notice (previous Revision: v3.4.1).SummaryDifference0.4%

- Check41 days agoChange DetectedNotice about government funding and NIH site operations added. The site version updated from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check48 days agoChange DetectedAdded a glossary toggle option and updated several metadata labels, including capitalization changes to 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data'. The revision identifier was updated to v3.4.0 (from v3.3.4). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check62 days agoChange DetectedA new Revision: v3.3.4 label was added and the previous Revision: v3.3.3 label was removed, indicating a minor site revision. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check69 days agoChange DetectedAn updated status block was added, displaying Northwestern University as sponsor and the last known status with a verification date (2023-12).SummaryDifference0.4%

Stay in the know with updates to Nivolumab and Ipilimumab in ACC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab and Ipilimumab in ACC Clinical Trial page.